Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia

Inclusion Criteria:

1. willing to receive the treatment and sign informed consent;
2. 18-60 years old (including 18 and 60), both gender;
3. HBsAg positive for at least 6 months and <1500IU/ml;
4. ALT≤1xULN and no elevated ALT has been detected in history;
5. HBV DNA detectable but<2000 IU/ml;
6. HBeAg negative ;

Exclusion Criteria:

1. For female participants: positive pregnancy test, presently breast-feeding, orunwillingness to use effective contraceptive measures for the duration of the study.For male participants: intent to procreate 3 months before or after the interventionor unwillingness to use effective measures of the contraception ;
2. neuropsychiatric diseases, such as depression, anxiety, mania, schizophrenia, or afamily history of mental illness (especially with a history of depression ordepression tendency);
3. co-infection of HCV, EBV, other hepatotropic viruses , non-hepatotropic viruses;
4. alcoholic hepatitis, drug-induced hepatitis, autoimmune liver disease;
5. Patients with moderate to severe steatohepatitis;
6. possibility of liver cirrhosis that cannot be excluded
7. hepatocellular carcinoma or AFP level>30ng/ml;
8. Kidney diseases: acute and chronic nephritis, renal insufficiency, nephrotic syndrome,serum creatinine> 1 x ULN at the time of screening;
9. at screening, the neutrophil count is less than 1.5×10^9/L, and the platelet count isless than 90×10^9/L;
10. Serum phosphorus level <0.7 mmol/L;
11. Antinuclear antibody (ANA)>1:100;
12. Autoimmune diseases, including thyroiditis, psoriasis and systemic lupuserythematosus;
13. Endocrine system diseases, including thyroid diseases and diabetes mellitus;
14. Uncontrolled blood pressure: SBP>160 mmHg or DBP >100 mmHg at the time of enrollment;
15. Evidence of cardiovascular disease, existing congestive cardiac failure on physicalexam and/or acute coronary syndrome in the past 6 months;
16. Severe retinopathy or other serious eye diseases;
17. Organic disease or dysfunction;
18. plan to receive an organ transplant or have already undergone an organ transplant;
19. received standardized treatment with interferon or NA products before .
20. allergic to interferon or pharmaceutical excipients, or meet any of thecontraindications in the experimental drug instructions;
21. Participated in other interventional trials within 3 months before the screening orother conditions deemed unsuitable by the investigator.